{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:37:52Z","timestamp":1757309872397},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ijrobp.2018.05.079","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T02:19:32Z","timestamp":1542248372000},"page":"1396-1399","source":"Crossref","is-referenced-by-count":1,"title":["Immune Therapies for Lymphomas: A Disruptive Technology With Opportunities for Radiation"],"prefix":"10.1016","volume":"102","author":[{"given":"Michael J.","family":"LaRiviere","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chelsea C.","family":"Pinnix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Plastaras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2018.05.079_bib1","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2015.64.9418","article-title":"Re-examining the role of radiation therapy for diffuse large B-cell lymphoma in the modern era","volume":"34","author":"Ng","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.05.079_bib2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.05.079_bib3","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.05.079_bib4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate nonredundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2018.05.079_bib5","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2018.05.079_bib6","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.05.079_bib7","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.05.079_bib8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2018.05.079_bib9","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2018.05.079_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/2040620716673787","article-title":"Emerging role of checkpoint blockade therapy in lymphoma","volume":"8","author":"Galanina","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.ijrobp.2018.05.079_bib11","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.05.079_bib12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.05.079_bib13","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2018.05.079_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2016.06.017","article-title":"Abscopal effect in a Hodgkin lymphoma patient treated by an antiprogrammed death 1 antibody","volume":"66","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2018.05.079_bib15","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2018.1452217","article-title":"An abscopal effect may augment PD-1 inhibition in refractory classical Hodgkin lymphoma","author":"Wight","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijrobp.2018.05.079_bib16","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"336","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.05.079_bib17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc971","article-title":"Targeting tumours with genetically enhanced T lymphocytes","volume":"3","author":"Sadelain","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ijrobp.2018.05.079_bib18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","article-title":"Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor","volume":"32","author":"Kochenderfer","year":"2009","journal-title":"J Immunother"},{"key":"10.1016\/j.ijrobp.2018.05.079_bib19","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.ijrobp.2018.05.079_bib20","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.05.079_bib21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fonc.2012.00191","article-title":"Radiation-induced effects and the immune system in cancer","volume":"2","author":"Kaur","year":"2012","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2018.05.079_bib22","first-page":"153","article-title":"Radiotherapy-induced lymphocytopenia: Changes in total lymphocyte count and in lymphocyte subpopulations under pelvic irradiation in gynecologic neoplasms","volume":"19","author":"Lissoni","year":"2005","journal-title":"J Biol Regul Homeost Agents"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301618309325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301618309325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T03:38:24Z","timestamp":1542253104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301618309325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0360301618309325"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2018.05.079","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}